<- Go Home

Accuray Incorporated

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Market Cap

$117.9M

Volume

727.2K

Cash and Equivalents

$63.3M

EBITDA

$7.8M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$139.4M

Profit Margin

30.93%

52 Week High

$2.95

52 Week Low

$1.03

Dividend

N/A

Price / Book Value

1.90

Price / Earnings

-5.79

Price / Tangible Book Value

29.14

Enterprise Value

$233.6M

Enterprise Value / EBITDA

10.41

Operating Income

$1.5M

Return on Equity

36.07%

Return on Assets

0.20

Cash and Short Term Investments

$63.3M

Debt

$179.1M

Equity

$61.9M

Revenue

$450.9M

Unlevered FCF

$28.8M

Sector

Health Care Equipment and Supplies

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches